MicroVention in the News

Sep 21, 2023

NeuroNews

Microvention enters transradial access market with US FDA clearance of Sofia EX catheter

Microvention, a wholly owned subsidiary of Terumo Corporation, announced today that the Sofia EX 5Fr 115cm intracranial support catheter received US Food and Drug Administration (FDA) 510(k) clearance on 15 September 2023 for use in transradial access in addition to transfemoral access.

Sep 21, 2023

Endovascular Today

MicroVention Sofia EX 5-F, 115-cm Intracranial Support Catheter Cleared for Transradial Access

MicroVention, Inc., a neurovascular company and wholly owned subsidiary of Terumo Corporation, announced that the Sofia EX 5-F, 115-cm intracranial support catheter has received FDA 510(k) clearance for transradial access in addition to transfemoral access.

Sep 21, 2023

CardiacVascular News

MicroVention Enters Transradial Access Therapy; Receives FDA Clearance of SOFIA™ EX 5F 115cm Intracranial Support Catheter

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the SOFIA™ EX 5F 115 cm Intracranial Support Catheter (Soft TOrqueable catheter For Intracranial Access) has received FDA 510(k) clearance on September 15, 2023, for transradial access in addition to transfemoral access.

Sep 12, 2023

NeuroNews

New Pathway to Neurosurgery programme intends to “open doors” for underrepresented groups

The Congress of Neurological Surgeons (CNS) Foundation has launched its Pathway to Neurosurgery programme, an initiative dedicated to alleviating healthcare disparities by encouraging high school students from underrepresented groups to pursue a career in neurosurgery or medicine.

Sep 8, 2023

Associated Press News

Groundbreaking Program Encourages Underrepresented Minorities to Consider Career in Neurosurgery

WASHINGTON, Sept. 8, 2023 /PRNewswire/ -- Today, the Congress of Neurological Surgeons (CNS) Foundation launched its Pathway to Neurosurgery program in Washington, DC. The initiative is dedicated to alleviating health care disparities by encouraging high school students from underrepresented groups to pursue a career in neurosurgery or medicine.

Aug 23, 2023

Neuro News

Continued improvement of flow diverters and intrasacculars holds key to truly advancing aneurysm care

Laurent Pierot’s (Reims University Hospitals, Reims, France) long career in the treatment of intracranial aneurysms predates not only what many consider to be the advent of the interventional neuroradiology (INR) specialty, the ISAT trial, but also the introduction of the Guglielmi detachable coil (GDC) in 1990.

Jul 31, 2023

Medical Buyer

MicroVention celebrates one-year anniversary of FRED X Flow Diverter

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, is celebrating the one-year anniversary of the company’s FRED™ X Flow Diverter. In close collaboration with physician partners across the United States, over 1,000 patients have been successfully treated with the FRED X device.

Jul 31, 2023

Yahoo!Finance

MicroVention Announces 5-Year Clinical Trial Data and Size Additions for its WEB Aneurysm Embolization System; WEB is Most Well-Studied Intrasaccular Device Available Today

MicroVention’s WEB System is the World Leader and Only PMA-Approved Intrasaccular Flow Disruptor; Advances Treatment of Wide-Neck Bifurcation Aneurysms with ONE Device

Jul 31, 2023

Endovascular Today

MicroVention Announces New Sizes of Web System and 5-Year WEB-IT Trial Data

MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced the addition of two sizes to its Web aneurysm embolization system. The Web system is now available in single-layer (SL) 6 X 2 mm and SL 7 X 2 mm sizes, which allow for the treatment of different sizes and shapes of aneurysms.

Jul 31, 2023

Bloomberg

MicroVention Celebrates One-Year Anniversary of FRED™ X Flow Diverter with Over 1,000 Patients Treated Across the U.S.

MicroVention Celebrates One-Year Anniversary of FRED™ X Flow Diverter with Over 1,000 Patients Treated Across the U.S. The FRED X Flow Diverter is the Next Generation in Flow Diversion Technology

Jul 31, 2023

NeuroNews

Microvention announces five-year WEB-IT data alongside two new device sizes

Microvention, a wholly owned subsidiary of Terumo Corporation, has announced the publication of five-year follow-up data from the WEB-IT trial and the addition of two sizes to its Woven EndoBridge (WEB) aneurysm embolisation system.

Jun 28, 2023

Endovascular Today

MicroVention Launches Eric Retrieval Device for Ischemic Stroke Treatment in United States

The Eric device joins a portfolio of stroke solutions from MicroVention including the Sofia catheter, Bobby balloon guide catheter, Wedge and Headway microcatheters, and Traxcess guidewire.

Jun 28, 2023

Medical Device Network

MicroVention announces commercial availability of ERIC device in US

Terumo’s wholly owned subsidiary MicroVention has announced the commercial availability of its ERIC Retrieval Device in the US for ischemic stroke treatment.

Jun 27, 2023

Yahoo Finance

MicroVention Reshapes Stroke Therapy with the Introduction of the ERIC™ Retrieval Device; ERIC Delivers Thrombus Control, Procedure Efficiency and Versatility When Every Second Counts

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the ERIC Retrieval Device is now commercially available in the United States for ischemic stroke treatment.

Jun 27, 2023

Cardiac Vascular News

MicroVention Reshapes Stroke Therapy with the Introduction of the ERIC™ Retrieval Device; ERIC Delivers Thrombus Control, Procedure Efficiency and Versatility When Every Second Counts

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the ERIC Retrieval Device is now commercially available in the United States for ischemic stroke treatment. ERIC received FDA 510(k) clearance on March 31, 2022.

May 23, 2023

NeuroNews

WEB 17 device maintains efficacy, safety across ruptured and unruptured aneurysms

The WEB 17 device has demonstrated positive efficacy and safety outcomes in the prospective, multicentre CLEVER study, indicating its utility for intrasaccular embolisation across ruptured and unruptured intracranial aneurysms. Twelve-month results from the study were recently delivered by Laurent Spelle (Bicêtre Hospital, Paris, France) at the LINNC Americas Seminar (16–17 March, Miami, USA).

Apr 11, 2023

The Associated Press

MicroVention Announces Continued Achievements with its Door to the Future Program with the Republic of Costa Rica; President Rodrigo Chaves Robles Signs National Employment Program Decree at MicroVention Today and Tours Door to the Future Lab

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today hosted the Republic of Costa Rica’s President Rodrigo Chaves Robles and other government officials and dignitaries at its Costa Rica facility in Alajuela.

Apr 11, 2023

MicroVention Announces Continued Achievements with its Door to the Future Program with the Republic of Costa Rica; President Rodrigo Chaves Robles Signs National Employment Program Decree at MicroVention Today and Tours Door to the Future Lab

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today hosted the Republic of Costa Rica’s President Rodrigo Chaves Robles and other government officials and dignitaries at its Costa Rica facility in Alajuela.

Dec 16, 2022

NeuroNews

How do we improve the treatment of stroke patients in the future?

Since its inception in 1997, MicroVention has gradually expanded its offerings from cerebral aneurysms to include several other areas in neuroendovascular care—with ischaemic stroke being a key area of focus over the past 15 years.

Sep 29, 2022

NeuroNews

Microvention celebrates 25 years in neuroendovascular technologies with ‘Patient’s Day’

Microvention, a wholly owned subsidiary of Terumo Corporation, today celebrated its 25-year anniversary in the neuroendovascular technologies industry.

Aug 15, 2022

NeuroNews

SNIS 2022: WEB flow diverter shown to be safe and effective in long-term cohort

The Society of NeuroInterventional Surgery’s19th annual meeting saw research involving the Woven EndoBridge (WEB; Microvention/Terumo) device disclosed for the first time, with co-principal investigator Adam Arthur (University of Tennessee Health Sciences Center and Semmes-Murphey Clinic, Memphis, USA) delivering a late-breaking presentation of five-year data from the WEB-IT trial.

Jun 13, 2022

NeuroNews

Multicentre study indicates WEB flow disrupters can safely be used in sidewall aneurysms

As per the findings of a multicentre, retrospective study, use indications for the Woven EndoBridge (WEB) intrasaccular flow disruption device (Microvention/Terumo) can be safely extended to include sidewall intracranial aneurysms.

Apr 22, 2022

Society of NeuroInterventional Surgery

MicroVention Announces First Patient Enrolled in the STRAIT Study with the New BOBBY™ Balloon Guide Catheter

MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced the successful completion of its first enrollment in a multi-center, prospective EU observational study called STRAIT, to evaluate the Safety and Performance of the BOBBY Balloon Guide Catheter for Endovascular Treatment of Acute Ischemic Stroke.